142 related articles for article (PubMed ID: 10601602)
1. Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells.
Yamamoto M; Ichinose K; Ishii N; Khoji T; Akiyoshi K; Moriguchi N; Sunamoto J; Kanematsu T
Oncol Rep; 2000; 7(1):107-11. PubMed ID: 10601602
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of polysaccharide coated liposomal adriamycin on AH66 hepatoma in nude mice.
Ichinose K; Yamamoto M; Khoji T; Ishii N; Sunamoto J; Kanematsu T
Anticancer Res; 1998; 18(1A):401-4. PubMed ID: 9568109
[TBL] [Abstract][Full Text] [Related]
3. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
4. Selective uptake by cancer cells of liposomes coated with polysaccharides bearing 1-aminolactose.
Matsukawa S; Yamamoto M; Ichinose K; Ohata N; Ishii N; Kohji T; Akiyoshi K; Sunamoto J; Kanematsu T
Anticancer Res; 2000; 20(4):2339-44. PubMed ID: 10953294
[TBL] [Abstract][Full Text] [Related]
5. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
Dong LF; Mei HS; Song SX; Lu ZJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):296-300. PubMed ID: 15862144
[TBL] [Abstract][Full Text] [Related]
6. [Fundamental studies of targeting cancer chemotherapy against choriocarcinoma--application of liposome].
Tadera S; Yamanaka N; Kamidono S
Hinyokika Kiyo; 1989 Feb; 35(2):209-15. PubMed ID: 2735231
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers.
Gabizon A; Goren D; Fuks Z; Barenholz Y; Dagan A; Meshorer A
Cancer Res; 1983 Oct; 43(10):4730-5. PubMed ID: 6883331
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
9. Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes.
Shimizu H; Kumai K; Uyama I; Shibata S; Tagawa T; Nagaike K; Yasuda T; Kitajima M; Tadakuma T
J Surg Oncol; 1996 Jul; 62(3):186-93. PubMed ID: 8667626
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
13. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
14. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes.
Yachi K; Suzuki N; Tanaka N; Okada K; Mitsui I; Kawato Y; Komagata Y; Komiyama K; Kikuchi H
Biopharm Drug Dispos; 1996 Nov; 17(8):699-715. PubMed ID: 8950048
[TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor effect of monkshood polysaccharide with adriamycin long circulating temperature-sensitive liposome and its mechanism].
Dong LF; Zhang YJ; Liu JS; Song SX; Hou J; Lu ZJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):458-62. PubMed ID: 16806008
[TBL] [Abstract][Full Text] [Related]
16. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes.
Han HD; Lee A; Hwang T; Song CK; Seong H; Hyun J; Shin BC
J Control Release; 2007 Jul; 120(3):161-8. PubMed ID: 17524514
[TBL] [Abstract][Full Text] [Related]
17. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
20. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
